Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity

Vaccine

Volumn 29, Issue 44, 2011, Pages 7618-7623

  An, So Jung ^a,b   Yoon, Yeon Kyung ^a   Kothari, Sudeep ^a   Kothari, Neha ^a   Kim, Jeong Ah ^a   Lee, Eugene ^a   Kim, Deok Ryun ^a   Park, Tai Hyun ^b   Smith, Greg W ^a   Carbis, Rodney ^a  

^a International Vaccine Institute   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Conjugation; Diphtheria toxoid; Vi polysaccharide

Indexed keywords

ADIPIC ACID; CARRIER PROTEIN; DIPHTHERIA TOXOID; TYPHOID VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONJUGATION; CONTROLLED STUDY; CROSS LINKING; DRUG RESPONSE; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOGENICITY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SALMONELLA TYPHI;

ADIPIC ACIDS; ANIMALS; ANTIBODIES, BACTERIAL; ANTITOXINS; DIPHTHERIA TOXOID; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; MICE; POLYSACCHARIDES, BACTERIAL; PROTEIN BINDING; TYPHOID-PARATYPHOID VACCINES; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 80053596363     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.019     Document Type: Article

References (28)

1. WHO Weekly epidemiological record no. 6; 2008, 49-60.
2. Khan M.I., Ochiai R.L., Clemens J.D. Population impact of Vi capsular polysaccharide vaccine. Expert Rev Vaccines 2010, 9(5):485-496.
3. Kingsley R.A., Dougan G. Typhoid fever. Vaccines for biodefense and emerging and neglected diseases 2009, 1147-1161. Academic Press, London. D.T.B. Alan, R.S. Lawrence (Eds.).
4. Crump J.A., Luby S.P., Mintz E.D. The global burden of typhoid fever. Bull World Health Organ 2004, 82(5):346-353.
5. DeRoeck D., Clemens J.D., Nyamete A., Mahoney R.T. Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine 2005, 23(21):2762-2774.
6. Robbins J.D., Robbins J.B. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi. J Infect Dis 1984, 150(3):436-449.
7. Robbins J.B., Schneerson R., Szu S.C., Fattom A., Yang Y., Lagergard T., et al. Prevention of invasive bacterial diseases by immunization with polysaccharide-protein conjugates. Curr Top Microbiol Immunol 1989, 146:169-180.
8. Stein K.E. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992, 165(Suppl. 1):S49-S52.
9. Szu S.C., Stone A.L., Robbins J.D., Schneerson R., Robbins J.B. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med 1987, 166(5):1510-1524.
10. Kossaczka Z., Bystricky S., Bryla D., Shiloach J., Robbins J., Szu S. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Infect Immun 1997, 65(6):2088-2093.
11. Jang H., Yoon Y.K., Kim J.A., Kim H.S., An S.J., Seo J.H., et al. Optimization of Vi capsular polysaccharide production during growth of Salmonella enterica serotype Typhi Ty2 in a bioreactor. J Biotechnol 2008, 135(1):71-77.
12. Kothari S., Kothari N., Lee E., Kim J.A., An S.J., Yoon Y.K., et al. Development of an efficient and scalable method for processing and purification of Vi capsular polysaccharide. Proc Vaccinol 2010, 2(1):78-81.
13. Lowry O.H., Rosebrough N.J., Farr A.L. Randall RJ protein measurement with Folin phenol reagent. J Biol Chem 1951, 193(1):265-275.
14. WHO WHO technical reports series, no. 840, 1994. Requirements for Vi polysaccharide typhoid vaccine 1994, WHO, Geneva, Switzerland.
15. Schneerson R., Barrera O., Sutton A., Robbins J.B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 1980, 152(2):361-376.
16. Hestrin S. The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application. J Biol Chem 1949, 180(1):249-261.
17. Cui C., Carbis R., An S.J., Jang H., Czerkinsky C., Szu S.C., et al. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates. Clin Vaccine Immunol 2010, 17(1):73-79.
18. Micoli F., Rondini S., Pisoni I., Proietti D., Berti F., Costantino P., et al. Vi-CRM197 as a new conjugate vaccine against Salmonella typhi. Vaccine 2011, 29(4):712-720.
19. Rondini S., Micoli F., Lanzilao L., Hale C., Saul A.J., Martin L.B. Evaluation of the immunogenicity and biological activity of Citrobacter freundii Vi CRM197 conjugates as a vaccine for S. typhi. Clin Vaccine Immunol 2011, 18:460-468.
20. Szu S.C., Taylor D.N., Trofa A.C., Clements J.D., Shiloach J., Sadoff J.C., et al. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun 1994, 62:4440-4444.
21. Kossaczka Z., Lin F.Y., Ho V.A., Thuy N.T., Van Bay P., Thanh T.C., et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 1999, 67(11):5806-5810.
22. Thiem V.D., Lin F.-Y.C., Canh D.G., Son N.H., Anh D.D., Mao N.D., et al. Vi conjugate typhoid vaccine (Vi-rEPA) is safe, elicits protective levels of IgG anti-Vi and is compatible with routine infant vaccines. Clin Vaccine Immunol 2011, 18:730-735.
23. Heyns K., Kiessling G. Strukturaufklarung des Vi-Antigens aus Citrobacter freundii (E. coli) 5396/38. Carbohydr Res 1967, 3:340-353.
24. Lindberg A.A. Glycoprotein conjugate vaccines. Vaccine 1999, 17(Suppl. 2):S28-S36.
25. Wessels M.R., Paoletti L.C., Guttormsen H-K., Michon F., D'Ambra A.J., Kasper D.L. Structural properties of Group B Streptococcal Type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy. Infect Immun 1998, 66(5):2186-2192.
26. Szu S.C., Li X.R., Schneerson R., Vickers J.H., Bryla D., Robbins J.B. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi. Infect Immun 1989, 57(12):3823-3827.
27. American Academy of Pediatrics Committee on infectious diseases: Haemophilus influenzae type b conjugate vaccines: recommendations for immunization with recently and previously licensed vaccines. Pediatrics 1993, 92:480.
28. Granoff D.M., Rathore M.H., Holmes S.J., Granoff P.D., Lucas A.H. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine 1993, 11(Suppl. 1):S46-S51.